[go: up one dir, main page]

CO2018002534A2 - Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos - Google Patents

Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos

Info

Publication number
CO2018002534A2
CO2018002534A2 CONC2018/0002534A CO2018002534A CO2018002534A2 CO 2018002534 A2 CO2018002534 A2 CO 2018002534A2 CO 2018002534 A CO2018002534 A CO 2018002534A CO 2018002534 A2 CO2018002534 A2 CO 2018002534A2
Authority
CO
Colombia
Prior art keywords
critical care
sedation
use during
care treatment
parenteral formulation
Prior art date
Application number
CONC2018/0002534A
Other languages
English (en)
Inventor
Matthew During
Anna Kazanchyan
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/834,027 external-priority patent/US9399034B1/en
Priority claimed from PCT/US2016/045094 external-priority patent/WO2017027249A1/en
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CO2018002534A2 publication Critical patent/CO2018002534A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proveen métodos de sedación a un paciente sometido a tratamiento de cuidado crítico utilizando gaboxadol intravenoso o una sal farmacéuticamente aceptable del mismo. Se proveen formulaciones parenterales para sedación en cuidado crítico utilizando gaboxadol o una sal farmacéuticamente aceptable del mismo. Las formulaciones parenterales son particularmente bien adecuadas para usarse en sedación para cuidado crítico.
CONC2018/0002534A 2015-08-11 2018-03-09 Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos CO2018002534A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562203731P 2015-08-11 2015-08-11
US201562203748P 2015-08-11 2015-08-11
US14/834,027 US9399034B1 (en) 2015-08-11 2015-08-24 Methods of sedation during critical care treatment
US15/185,650 US9717716B2 (en) 2015-08-11 2016-06-17 Methods of sedation during critical care treatment
PCT/US2016/045094 WO2017027249A1 (en) 2015-08-11 2016-08-02 Methods of sedation and parenteral formulation for use during critical care treatment

Publications (1)

Publication Number Publication Date
CO2018002534A2 true CO2018002534A2 (es) 2018-05-31

Family

ID=59687449

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0002534A CO2018002534A2 (es) 2015-08-11 2018-03-09 Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos

Country Status (12)

Country Link
US (1) US20180235942A1 (es)
EP (1) EP3334427A4 (es)
JP (1) JP6857647B2 (es)
KR (1) KR20180048707A (es)
CN (1) CN108135889A (es)
AU (1) AU2016304737B2 (es)
CA (1) CA2994952A1 (es)
CO (1) CO2018002534A2 (es)
IL (1) IL257296B2 (es)
MX (1) MX394213B (es)
PE (1) PE20181332A1 (es)
TW (1) TWI763632B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170014393A1 (en) 2015-07-17 2017-01-19 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
BR112019002538A2 (pt) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
CN112930182A (zh) 2018-09-20 2021-06-08 奥维德医疗公司 加波沙朵用于治疗图雷特综合征、抽搐和口吃的用途
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
US20220218740A1 (en) * 2020-10-25 2022-07-14 Vaporworks Nursing Anesthesia Inc. Opioid-free compositions for anesthesiological applications and related methods and systems

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071933A (en) * 1999-12-03 2000-06-06 Diversified Medical Innovations, Inc. Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
EP1742624B1 (en) * 2004-02-18 2010-01-06 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
US9399034B1 (en) * 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
AU2016304737B2 (en) 2021-03-11
TW201717944A (zh) 2017-06-01
IL257296B2 (en) 2023-02-01
EP3334427A4 (en) 2019-02-06
EP3334427A1 (en) 2018-06-20
JP6857647B2 (ja) 2021-04-14
MX394213B (es) 2025-03-24
CA2994952A1 (en) 2017-02-16
CN108135889A (zh) 2018-06-08
JP2018522920A (ja) 2018-08-16
KR20180048707A (ko) 2018-05-10
AU2016304737A1 (en) 2018-02-22
IL257296A (en) 2018-03-29
MX2018001720A (es) 2018-09-06
TWI763632B (zh) 2022-05-11
US20180235942A1 (en) 2018-08-23
IL257296B (en) 2022-10-01
PE20181332A1 (es) 2018-08-20

Similar Documents

Publication Publication Date Title
CO2018002534A2 (es) Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
CY1122671T1 (el) Θεραπευτικως δραστικες ενωσεις και οι μεθοδοι χρησεις αυτων
CY1124368T1 (el) Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
MX2018000777A (es) Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
CR20140086A (es) Tratamientos de combinación para hepatitis c
MX376329B (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
IL285440A (en) Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
CL2016003260A1 (es) Profármacos de gemcitabina
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
CL2017000050A1 (es) Terapia de combinación para el cáncer
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
HUE058151T2 (hu) Enterococcusból származó flagellin készítményei terápiában történõ alkalmazásra
MX2019014024A (es) Tratamiento de los trastornos depresivos.
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
MX381617B (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.